Oracle Partners Commences Legal Action Against Biolase, Inc.

         Oracle Partners Commences Legal Action Against Biolase, Inc.

Seeks to Enjoin Unlawful Action

PR Newswire

GREENWICH, Conn., March 12, 2014

GREENWICH, Conn., March 12, 2014 /PRNewswire/ --Oracle Partners, L.P.
("Oracle"), Biolase, Inc.'s ("Biolase" or the "Company") (Nasdaq: BIOL)
largest shareholder, announced that it has commenced legal action in the
Delaware Court of Chancery against the Company seeking to enjoin action in
violation of the Company's Bylaws and Delaware law. The unlawful action
occurred when the Company, without approval of the Board, purportedly expanded
the Company's Board of Directors from six to eight directors and reappointed
two directors who had previously resigned from the Board. Specifically:

  oOn, February 28, 2014, two current Board members, Dr. Alexander K. Arrow
    and Dr. Sam Low tendered their resignations as directors of the Company
    and two independent new directors, Mr. Jeffrey M. Nugent and Mr. Paul N.
    Clark, were appointed by the Board to fill the resulting two vacancies.
  oBiolase publicly announced these events in a press release on March 3,
    2014 and stated that its Board consists of six directors.
  oOn March 6, 2014, the Company filed a Form 8-K with the Securities and
    Exchange Commission reporting the appointments of Messrs. Clark and Nugent
    to the Board, but claiming the size of the Board somehow to be increased
    to eight members because Mr. Pignatelli claims after-the-fact not to have
    accepted the resignations of Drs. Arrow and Low.
  oUnder both the Company's own Bylaws and as a matter of Delaware law,
    director resignations become effective immediately and are effective
    whether or not accepted by the Company or the Board.
  oSince the vacancies created by Drs. Arrow's and Low's resignations were
    subsequently filled by Messrs. Clark and Nugent, there were no Board
    vacancies remaining to which Drs. Arrow and Low could be reappointed.
  oAny expansion of the Board from six to eight members and any reappointment
    of Drs. Arrow and Low require action by a majority of the Board, neither
    of which is purported to have occurred.

Larry Feinberg, the Managing Member of Oracle's general partner stated: "What
seems to have occurred is a manipulation of the Board at the behest of the
Chairman and CEO in an effort to protect his positions at the Company. We
therefore have taken action against the Company in Delaware Court to prevent
this unlawful activity."

Oracle's action in Delaware seeks the following relief:

  oA declaratory judgment that the resignations of each of Drs. Arrow and Low
    were effective on February 28, 2014, when those resignations were
    communicated to the Company or its Board, and that neither Dr. Arrow nor
    Dr. Low is currently a member of the Board.
  oA declaratory judgment that the Board currently consists of only six
    members, not eight as falsely claimed by the Company in its March 6 Form
    8-K.
  oAn Order temporarily, preliminarily and permanently enjoining Biolase and
    its Board from taking any actions unless they are approved by at least
    four of the Biolase directors, excluding any votes of Drs. Arrow or Low,
    whose directorships are vehemently disputed.

Oracle Partners previously announced its nomination of four independent
directors for election to the Biolase Board in response to these unlawful
actions in furtherance of management and Board entrenchment, as well as the
poor operating and financial performance of the Company.

Mr. Feinberg added: "Unlawful actions regarding Board composition cannot
stand. We have brought our action in Delaware court for the benefit of all
shareholders and intend to vigorously pursue and enforce shareholders'
rights."

About Oracle Partners, L.P.

Oracle Partners is a fundamental-research driven investment fund that is
exclusively focused on the global healthcare and bioscience industries.

Additional Information and Where to Find It

Oracle Partners, L.P., Oracle Institutional Partners, L.P., Oracle Ten Fund
Master, L.P., Oracle Associates, LLC, Oracle Investment Management, Inc. and
Larry N. Feinberg (collectively, "Oracle"), together with Paul N. Clark,
Jeffrey M. Nugent, Frederic H. Moll and Eric Varma, are participants in the
solicitation of proxies from stockholders in connection with the 2014 Annual
Meeting of Stockholders (the "Annual Meeting") of Biolase, Inc. (the
"Company"). Oracle intends to file a proxy statement (the "2014 Proxy
Statement") with the Securities and Exchange Commission (the "SEC") in
connection with the solicitation of proxies for the Annual Meeting.

Oracle may be deemed to beneficially own 6,105,383 shares of the Company's
common stock, representing approximately 16.4% of the Company's outstanding
common stock. None of the other participants owns in excess of 1% of the
Company's common stock. Additional information regarding such participants,
including their direct or indirect interests, by security holdings or
otherwise, will be included in the 2014 Proxy Statement and other relevant
documents to be filed with the SEC in connection with the Annual Meeting.

Promptly after filing its definitive 2014 Proxy Statement with the SEC, Oracle
intends to mail the definitive 2014 Proxy Statement and an accompanying proxy
card to some or all stockholders pursuant to applicable SEC rules.
STOCKHOLDERS ARE URGED TO READ THE 2014 PROXY STATEMENT (INCLUDING ANY
AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE
COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, copies
of the definitive 2014 Proxy Statement and any other documents filed by Oracle
with respect to the Company with the SEC in connection with the Annual Meeting
at the SEC's website (http://www.sec.gov) or by writing to Oracle Partners,
L.P., 200 Greenwich Avenue, Greenwich, CT 06830.

SOURCE Oracle Partners, L.P.

Contact: Oracle Partners, L.P., Aileen Wiate, Chief Financial Officer, (203)
862-7900 or BMC Communications, Brad Miles, CEO, 646.513.3125
 
Press spacebar to pause and continue. Press esc to stop.